Drugs / BCMA/CD70 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07318259 | Jan → Jul 2026 overdue | systemic lupus erythematosus | Chongqing Precision Biotech Co., Ltd | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA/CD70 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07318259 ↗ |
| Action | Deplete | “eliminate target cells expressing disease-related antigens through antigen-specific recognition” NCT07318259 ↗ |
| Modality | Cell therapy | “CAR-T therapy is an adoptive cell therapy that uses genetic modification technology to reprogram T cells and eliminate target cells expressing disease-related antigens through...” NCT07318259 ↗ |